Jazz and Concert Collaborate to Develop Deuterium-Modified Version of Xyrem®

Abstract

Jazz Pharmaceuticals has licensed exclusive worldwide rights to develop and commercialise Concert Pharmaceuticals’ deuterium-modified analogues of sodium oxybate (D-SXB), including its lead compound C-10323. In doing so, the company is looking to develop a follow-on version of its key commercial asset Xyrem® (sodium oxybate), which is indicated for the treatment of cataplexy and excessive daytime sleepiness in narcolepsy patients. Preclinical data suggest that selective deuterium incorporation can stabilise sodium oxybate in vivo, which could provide for an improved dosing schedule. An IND application for C-10323 is planned for later in 2013.